Stock Forecast

  BioCryst Pharmaceuticals, Inc. ( BCRX) Stock. Should you Buy or Sell?    $ 13.45

-0.28 (-2.13 %)

BioCryst Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol BCRX
Price $13.45
Beta 2.195
Volume Avg. $2.94 M
Market Cap $2.5 B
52 Week Range $7.61 - $19.99

BioCryst Pharmaceuticals, Inc. opened the day at $13.45 which is -2.13 % on yesterday's close. BioCryst Pharmaceuticals, Inc. has a 52 week high of $19.99 and 52 week low of $7.61, which is a difference of $12.38. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $2.5 B and total net profit is $157170000 which means the company is trading at 15.91 times profit to market capitalization. Theoretically, if you were to buy BioCryst Pharmaceuticals, Inc. for $2.5 B, it would take 15 years to get your money back. BioCryst Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


BioCryst Pharmaceuticals, Inc. Stock Forecast - Is BioCryst Pharmaceuticals, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreBuy
ROA ScoreSell
DE ScoreStrong Sell
PE ScoreStrong Sell
PB ScoreStrong Sell
Overall RecommendationSell

Growth and Value

PE Ratio -11.908
Dividend Yiel 0.000
Net Profit Margin -1.030

Valuing BioCryst Pharmaceuticals, Inc.

Price Book Value Ratio -11.707 Price To Book Ratio -11.707
Price To Sales Ratio 12.261 Price Earnings Ratio -11.908

How liquid is BioCryst Pharmaceuticals, Inc.

Current Ratio 5.188
Quick Ratio 4.812


Debt Ratio 1.418 Debt Equity Ratio -3.394
Long Term Debt To Capitalization -2.411 Total Debt To Capitalization -2.531

Latest news about BioCryst Pharmaceuticals, Inc.

Options Bulls Blast Phama Stock on Lifted Clinical Hold

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is soaring today, last seen up 22.5% at $13.65, after the drug maker said the U.S. Food and Drug Administration (FDA) lifted a partial clinic hold on its blood disorder treatment program.

Date : 04/08/2022

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 Results - Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Anthony Doyle - CFO Dr. Bill Sheridan - CMO Charlie Gayer - CCO Dr. Helen Thackray - Chief R&D Officer Conference Call Participants Stacy Ku - Cowen and Company Jon Wolleben - JMP Securities Chris Raymond - Piper Sandler Jessica Fye - JPMorgan Maury Raycroft - Jefferies Gena Wang - Barclays Brian Abrahams - RBC Capital Markets Serge Belanger - Needham & Company Liisa Bayko - Evercore ISI Operator Welcome to the BioCryst Second Quarter 2022 Earnings Conference Call. My name is Vanessa and I will be your operator for today's call.

Date : 04/08/2022

Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

The FDA has lifted the partial clinical hold on the biotech's kidney disease drug.

Date : 04/08/2022

3 Fast-Growing Stocks to Buy Now

ShockWave, Vir, and BioCryst are all seeing skyrocketing sales this quarter.

Date : 31/07/2022

BioCryst to Report Second Quarter 2022 Financial Results on August 4

RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022.

Date : 21/07/2022

About BioCryst Pharmaceuticals, Inc.

CEO : Mr. Jon Stonehouse
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Global Select

Description :

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

My Newsletter

Sign Up For Updates & Newsletters